SCHEMBL5749155

SCHEMBL5749155

Cc1ccc(S(=O)(=O)N2CCC(c3ncccn3)CC2)cc1CC(=O)O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.47
GAA P10253 2/20 0.47
KDM4E B2RXH2 1/20 0.47
HTT P42858 1/20 0.46
MAPT P10636 1/20 0.44
NPC1 O15118 1/20 0.44
MAPK1 P28482 2/20 0.44
USP2 O75604 1/20 0.44
ALOX15 P16050 1/20 0.44
HSD17B10 Q99714 1/20 0.44
PTGDR2 Q9Y5Y4 1/20 0.43
USP5 P45974 3/20 0.43
TDP1 Q9NUW8 2/20 0.43
POLB P06746 2/20 0.43
CHRM5 P08912 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
APEX1 P27695 2/20 0.42
ALDH1A1 P00352 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5750003 0.85 GAA (0.43) TSHRGAAKDM4EHTTMAPT
SCHEMBL6350461 0.83 SMN1; SMN2 (0.56) TSHRGAAKDM4EHTTMAPK1
SCHEMBL5746178 0.82 USP5 (0.58) TSHRGAAKDM4EMAPTPTGDR2
SCHEMBL5750977 0.81 PTGDR (0.50) TSHRGAAKDM4EHTTMAPT
SCHEMBL5749414 0.79 USP5 (0.52) GAAPTGDR2USP5HDAC6
SCHEMBL5746850 0.78 PTGDR2 (0.42) TSHRGAAKDM4EHTTMAPT
SCHEMBL5747078 0.77 MEN1 (0.66) GAAMAPTPOLBMEN1KMT2A
SCHEMBL5770088 0.76 HSD11B1 (0.66)
SCHEMBL5748050 0.74 PTPN11 (0.47) KDM4EHTTPTGDR2HDAC6MEN1
SCHEMBL5799838 0.74 PKM (0.47) TSHRGAAHTTMAPTPTGDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1735280-A1 ARYL SULFONAMIDE AND SULFONYL COMPOUNDS AS MODULATORS OF PPAR AND METHODS OF TREATING METABOLIC DISORDERS Kalypsys, Inc. (US) 2006-12-27 EP disclosed
WO-2005115983-A1 ARYL SULFONAMIDE AND SULFONYL COMPOUNDS AS MODULATORS OF PPAR AND METHODS OF TREATING METABOLIC DISORDERS KALYPSYS, INC. (US) 2005-12-08 WO disclosed
US-20050234046-A1 Aryl sulfonamide and sulfonyl compounds as modulators of PPAR and methods of treating metabolic disorders KALYPSYS, INC. (US) 2005-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050234046-A1 Aryl sulfonamide and sulfonyl compounds as modulators of PPAR and methods of treating metabolic disorders PPARA, PPARG, PPARD TSHR 140/4885GAA 172/4885KDM4E 3692/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.